Dr. deVere White is associate dean for cancer programs at UC Davis School of Medicine, director of the UC Davis Comprehensive Cancer Center and a professor of urology. He received his medical degree from Dublin University in Dublin, Ireland, and completed an internship and residencies in surgery and urology at St. Vincent’s Hospital in Dublin and at Duke University Medical Center in Durham, NC.
The author of more than 300 peer-reviewed scientific articles and book chapters, Dr. deVere White serves on the editorial boards of six international scientific journals. His current research efforts focused on the molecular events that govern the response of prostate and bladder cancer to targeted therapies, the biomolecular mechanisms that make some prostate cancers more virulent than others, and new methods of diagnosing and treating prostate cancer.
He is the immediate past president-elect of the Society of Urologic Oncology, a member of the Clinical Society of Genitourinary Surgeons and an elected member of the prestigious American Association of Genitourinary Surgeons. He has been named multiple times as one of "The Best Doctors in America" and is one of four urologists serving as a volunteer consultant to the American Cancer Society's on-line "Experts Answers" bulletin board for questions about prostate cancer.
Director, UC Davis Comprehensive Cancer Center
Codman-Radke Chair in Cancer Research
Distinguished Professor in Urology
St. Vincent?s Hospital, Dublin, Ireland, 1970-74
American Association of Anatomists
American Association of Genitourinary Surgeons
American Cancer Society
American Fertility Society
American Medical Association
American Urological Association
Northern California Oncology Group
Northern California Urological Society
Past President, Society of Urologic Oncology
Select Honors and Awards:
Huggins Award for Lifetime Achievement, 2013
Komen Promise Award, 2012
Healthcare Hero, Sacramento Business Journal, 2012
Elected to ?Best Doctors in America?, Best Doctors Inc., 2012
UC Davis School of Medicine Research Award, 2011
UCDMG Most Distinguished Graduate Award, Dublin Ireland, 2006
Listed in 2005-2006 "The Best Doctors in America" national reference directory (Woodward White Inc., publishers), 2005
Excellence in Mentoring Prize, UC Davis School of Medicine, 2004
"Spirit Project," State of California Lieutenant Governor, Cruz M Bustamante, 2003
Strathmore?s ?Who?s Who? Lifetime Member Award, 2003
Select Recent Publications:
Amir S, Ma A-H, Shi X-B, Xue L, Kung H-J, et al. (2013) Oncomir miR-125b Suppresses p14ARF to Modulate p53-Dependent and p53-Independent Apoptosis in Prostate Cancer. PLoS ONE 8(4): e61064. doi:10.1371/journal.pone.0061064
Liu C, Zhu Y, Lou W, Nadiminty N, Chen X, Zhou Q, Shi XB, deVere White RW, Gao AC. Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate 73(4):418-427. (2013)
Jung C, Iyengar S, Blahnik K, Jiang J, Tahimic C,Torok N, deVere White RW, Farnham P and Zern M. Human ESC self-renewal promoting miRNAs induce epithelial-mesenchymal transplant hepatocytes by controlling the PTEN and TTGB tumor suppressor signaling pathway. Molecular Cancer Research, 10(7):979-991. (2012)
Lin TY, Li YP, Zhang H, Luo J, Goodwin N, Gao T, deVere White RW, Lam KS, Pan CX. Tumor-targeting multifunctional micelles for imaging and chemotherapy of advanced bladder cancer. Nanomedicine (Long). 2012 Dec 2 [Epub ahead of print].
Shi, XB, Xue L, Ma, A-H, Tepper CG, Gandour-Edwards R, Kung H-J, deVere White RW. Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene, Oct 15. doi: 10.1038/onc.2012.425
Mooso BA, Vinall RL, Tepper CG, Savoy RM, Cheung JP, Singh S, Siddiqui S, Wang Y, Bedolla RG, Mudryj M, deVere White RW and Ghosh PM. Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization. Endocr Relat Cancer. 19(6):759-777. (2012)
Vinall RL, Kent MS, deVere White RW. Expression of microRNAs in urinary bladder samples obtained from dogs with grossly normal bladders, inflammatory bladder disease, or transitional cell carcinoma. Am J Vet Res. 2012 Oct:73(10):1626-33.
Nadiminity N, Tummala R, Lou W, Zhu Y, Shi XB, Zou JX, Chen HW, Zhang J, Chen X, Luo J, deVere White RW, Kung HJ, Evans CP, Gao AC.“MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. PLoS One. 7(3)e32832. Epub 2012 Mar 30.
Sarachine MJ, Buchholz BA and deVere White RW. Stem-like cells in bladder cancer cell lines with differential sensitivity to cisplatin. Anticancer Research 32:733-738.
Vinall RL, Chen JQ, Hubbard NE, Suaimon SS, deVere White RW, and Borowsky AD. Initiation of prostate cancer in mice by Tp53R270: an alternative molecular progression. Disease Models & Mechanisms, 2012 May 31. [Epub ahead of print]
Jacobson MC, deVere White RW and Demos SG. In vivo testing of a prototype system providing simultaneous white light and near infrared autofluorescence image acquisition for detection of bladder cancer. Journal of Biomedical Optics, 17(3). (2012)
Berglund RK, Tangen CM, Powell IS, Lowe BA, Haas GP, Carroll PR, Canby-Hagino ED, deVere White RW, Hemstreet GP, Crawford ED, Thompson IM and Klein EA. Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: Update on Southwest Oncology Group Study 9109. Urology 79(3) 633-637. (2012)
Lin TY, Zhang H, Luo J, Li Y, Gao T, Lara PN, deVere White RW, Lam KS and Pan C-X. Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer. Inter J of Nanomed, 2012:7 1-12.
Vinall RL, Ripoll AZ, Wang S, Pan CX and Devere White RW. MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status. Int J Cancer, 130(11): 2526-2538, 2012.